Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone (Q35024279)

5 August 2017

title

Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone (English)

1 reference

5 August 2017

main subject

autism spectrum disorder

0 references

0 references

1 reference

Yaowaluck Hongkaew

1 reference

5 August 2017

Nattawat Ngamsamut

1 reference

5 August 2017

Apichaya Puangpetch

1 reference

5 August 2017

Natchaya Vanwong

1 reference

5 August 2017

Pornpen Srisawasdi

1 reference

5 August 2017

Montri Chamnanphon

1 reference

5 August 2017

Bhunnada Chamkrachchangpada

1 reference

5 August 2017

Teerarat Tan-Kam

1 reference

5 August 2017

Penkhae Limsila

1 reference

5 August 2017

Chonlaphat Sukasem

1 reference

5 August 2017

language of work or name

English

0 references

publication date

22 January 2015

1 reference

Neuropsychiatric Disease and Treatment

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

191-196

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

5 August 2017

start time

1 January 2015

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Elevated prolactin levels in male youths treated with risperidone and quetiapine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Antipsychotic-induced hyperprolactinemia and testosterone levels in boys

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and youn

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Elevation of prolactin levels by atypical antipsychotics

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

Prolactin levels and adverse events in patients treated with risperidone

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309788

25 October 2018

Identifiers

DOI

10.2147/NDT.S76276

1 reference

5 August 2017

1 reference

5 August 2017

1 reference